Browse the corpus

Index Child-Pugh class C disease, 40 41 Discoid lupus erlthematosus, 113t, 114-115, 115f Chlamydia screening, 6, 7t Disease modi8/ing antirheumatic drug therapy, 41 Chlomy dia trachomatis. 52 Doxycycline, phototoxic reactions to, Q95 Chlorhexidine washes. 99 DRESS slmdrome (drug induced hypersensitivity syndrome), 9t-93 Choosing Wisely campaign, 1, 24 Drug reactions, 921, lo4f Chronic disease screening, 4 6 Drug induced hypersensitivity syndrome (DRESS syndrome), 91 93, 93f Chronic kidney disease (CKD), 40 Drug-related eruptions, 91. See also specrflc type Chronic loose stool. 47t Dryeye,77 72 Chronic obstructive pulmonary disease (COPD), 341, 35, Q21, Q23 Dual antiplatelet therapy (DAPT), perioperative, 38 Chronic pelvic pain (CPP), 63 64, 64t Duke Activity Status Index (DASI), 33t Cicatricial pemphigoid, 1031 Dumping syndrome, 47t Cirrhosis, surgical risks in, Q74 Dyshidrotic eczema, 88f Climate change, human health and, 17 Dyslipidemia screening, 5 Clindamycin,9T Dysmenorrhea,6l, Q96 Clinical breast examination. 55 Dyspareunia, 65 Clinical decision support, 211, 24, Q3 Dysphagia, aspiration and, 28 Clomipramine,4S Dysplastic nevi, 121, 1211 Q110 Closed loop communication, 26t Clue cells, 65, 65f E

Child-Pugh class C disease, 40 41 Discoid lupus erlthematosus, 113t, 114-115, 115f Chlamydia screening, 6, 7t Disease modi8/ing antirheumatic drug therapy, 41 Chlomy dia trachomatis. 52 Doxycycline, phototoxic reactions to, Q95 Chlorhexidine washes. 99 DRESS slmdrome (drug induced hypersensitivity syndrome), 9t-93 Choosing Wisely campaign, 1, 24 Drug reactions, 921, lo4f Chronic disease screening, 4 6 Drug induced hypersensitivity syndrome (DRESS syndrome), 91 93, 93f Chronic kidney disease (CKD), 40 Drug-related eruptions, 91. See also specrflc type Chronic loose stool. 47t Dryeye,77 72 Chronic obstructive pulmonary disease (COPD), 341, 35, Q21, Q23 Dual antiplatelet therapy (DAPT), perioperative, 38 Chronic pelvic pain (CPP), 63 64, 64t Duke Activity Status Index (DASI), 33t Cicatricial pemphigoid, 1031 Dumping syndrome, 47t Cirrhosis, surgical risks in, Q74 Dyshidrotic eczema, 88f Climate change, human health and, 17 Dyslipidemia screening, 5 Clindamycin,9T Dysmenorrhea,6l, Q96 Clinical breast examination. 55 Dyspareunia, 65 Clinical decision support, 211, 24, Q3 Dysphagia, aspiration and, 28 Clomipramine,4S Dysplastic nevi, 121, 1211 Q110 Closed loop communication, 26t Clue cells, 65, 65f E Coagulation studies, preoperative, 29t Echinacea.2ot Coagulopathies, perioperative management, 38 39 Ecthyma,105 106,106f Cognitive disorder screening, 5 Ectoparasites, 111 116, l11t Colds, common,79, Q42 Ectopic pregnancy, 63 Colonscopy, l0t Edinburgh Postnatal Depression Scale, 5 Colorectal cancer screening, 10 11, 101, Q67 Electrocardiography (ECG), preoperative, 32-33 Co management, consultation and,25 27 Electrolltes, preoperative testing, 29t Combined hormonal contraception (CHC), 56 Electronic health record (EHR), 24, Q3 Comedos, characteristics of, 83t Emergenry Care Research Institute (ECRD, 3 Common co1ds,79 Endometrial cancer, evaluation ol Q45 Communication Endophthalmitis, 68 closed loop, 26t Enterovirus, conjunctivitis and, 68 hospital based strategies, 26t Epidermolysis bullosa acquista, l03t interprofessional, 25 Epi dermophAton spp., 106 Complications, prevention strategies, 27 28 Epididymal cysts, 52-53 Computerized clinical decision support (CDS), 24, Q3 Epididymitis, s2t, Q94 Computerized physician order entry (CPOE), 24, Q3 Epididymo orchitis, 52t Condyloma acuminata, 119 120, 119f Epiglottitis, 80, 801 Q89 conjunctivitis, 68,68f, Q17, Q66, Q125 Episcleritis, 69 70, 7of , Q1o2 Consultation, co management and, 25-27 Epistaxis,78-79 Contact dermatitis, ST 88,871 871,88f, Q76 Erectile dysfunction (ED), 46 48, 491, Q13, Q51 Contraception, 49 50, 56-58, 571, Q14, Q64 Erythema multiforme (EM), 941, 127 Corneal ercsions,70 71 Erythema nodosum, 127 128, 127f, 728t Cornea.72 Erythrasma, 106, 107f, Q103 Corns. 120 Erythroderma, 128, 728f , 128t, Q24 Coronary artery disease, 33 34, Q51 Erythromycin, 68,97 Costochonddtis. 56 Estrogen-progesterone contraception, 56 Coxsackievirus, conjunctivitis and, 68 Evening primose oil, 20t I Cranberry 20t Exanthematous drug eruptions, 91, Q10 Creams, characteristics of, 85t Excoriation, characteristics of, 83t Creatinine, preoperative testing, 29t Exercise for obesity, 44 Cremasteric reflex, 52 Expectant management, Q18 Crusts, characteristics of, 83t Eye disorders, 67-75 Culturally sensitive care, Q18 Cutaneous T-cell lymphoma, 128, 128i 1281 F Cutib acte rium acnes. 97 Falls, prevention of, 28 Cuticles, ragged, 1161 Famciclovir. 110 g/sts, characteristics ol 83t Fecal immunohistochemical test (FIT), Q67 Dreast.55 Female sexual dysfunction, 64 65 epididymal, 55 Finasteride, 114 ovarian, 63, 64t Fissures, characteristics of, 83t Fixed drug eruptions, 91, 93f D Roppy iris syndrome, 51 Danazol.56 5 Fluoroumcil. 124 Delayed hlpersensitivity reactions, 87 Foam medications, characteristics of, 85t Delirium, 27-28,2aL 41, 42 Folate associated disease/disorders, 18t Dental caries, 81 82,81f Folic acid supplementation, 59 Depression, 5, 47t,64 Fondaparinux,35 Dermatitis.86 87 Fracture risk in osteoporosis, Q55 Dermatitis herpetiformis, 103t Frailty, definition ol 41 Dermatofibromas, 120, 120f Frailty screening, Q21 Dermatologic disorders, 82 129, 83t, 85t Fungal infections, 65,67,83,101, 108, 108f, 116f, Q48 Dermatoph),tes, 106 108 Fusobocterium necrophorum, 80 Dermatoses, 102, 126 Dermographism, 90 91, 91f G Diabetes mellitus, 5, 39, Q47, Q109 Gallstones, 47t Dicloxacillin. 106 Garlic,20t Diet, modificationin. 43 44 Gastric banding,4S Dietary fiber, associated disease/disorders, 18t Gastric outlet syndrome, 47t Dietary supplements, 18-19 Gastric ulceration, 47t Dihydroxltestosterone, 52 Gastroesophageal refl ux, 47t Diphtheria toxoid, 12-13, Q40, Q63 Gastrointestinal agents, perioperative medication management, 3Ot Direct oral anticoagulants (DOACS), 35, 37 Gel medications, characteristics of, 85t

Coagulation studies, preoperative, 29t Echinacea.2ot Coagulopathies, perioperative management, 38 39 Ecthyma,105 106,106f Cognitive disorder screening, 5 Ectoparasites, 111 116, l11t Colds, common,79, Q42 Ectopic pregnancy, 63 Colonscopy, l0t Edinburgh Postnatal Depression Scale, 5 Colorectal cancer screening, 10 11, 101, Q67 Electrocardiography (ECG), preoperative, 32-33 Co management, consultation and,25 27 Electrolltes, preoperative testing, 29t Combined hormonal contraception (CHC), 56 Electronic health record (EHR), 24, Q3 Comedos, characteristics of, 83t Emergenry Care Research Institute (ECRD, 3 Common co1ds,79 Endometrial cancer, evaluation ol Q45 Communication Endophthalmitis, 68 closed loop, 26t Enterovirus, conjunctivitis and, 68 hospital based strategies, 26t Epidermolysis bullosa acquista, l03t interprofessional, 25 Epi dermophAton spp., 106 Complications, prevention strategies, 27 28 Epididymal cysts, 52-53 Computerized clinical decision support (CDS), 24, Q3 Epididymitis, s2t, Q94 Computerized physician order entry (CPOE), 24, Q3 Epididymo orchitis, 52t Condyloma acuminata, 119 120, 119f Epiglottitis, 80, 801 Q89 conjunctivitis, 68,68f, Q17, Q66, Q125 Episcleritis, 69 70, 7of , Q1o2 Consultation, co management and, 25-27 Epistaxis,78-79 Contact dermatitis, ST 88,871 871,88f, Q76 Erectile dysfunction (ED), 46 48, 491, Q13, Q51 Contraception, 49 50, 56-58, 571, Q14, Q64 Erythema multiforme (EM), 941, 127 Corneal ercsions,70 71 Erythema nodosum, 127 128, 127f, 728t Cornea.72 Erythrasma, 106, 107f, Q103 Corns. 120 Erythroderma, 128, 728f , 128t, Q24 Coronary artery disease, 33 34, Q51 Erythromycin, 68,97 Costochonddtis. 56 Estrogen-progesterone contraception, 56 Coxsackievirus, conjunctivitis and, 68 Evening primose oil, 20t I Cranberry 20t Exanthematous drug eruptions, 91, Q10 Creams, characteristics of, 85t Excoriation, characteristics of, 83t Creatinine, preoperative testing, 29t Exercise for obesity, 44 Cremasteric reflex, 52 Expectant management, Q18 Crusts, characteristics of, 83t Eye disorders, 67-75 Culturally sensitive care, Q18 Cutaneous T-cell lymphoma, 128, 128i 1281 F Cutib acte rium acnes. 97 Falls, prevention of, 28 Cuticles, ragged, 1161 Famciclovir. 110 g/sts, characteristics ol 83t Fecal immunohistochemical test (FIT), Q67 Dreast.55 Female sexual dysfunction, 64 65 epididymal, 55 Finasteride, 114 ovarian, 63, 64t Fissures, characteristics of, 83t Fixed drug eruptions, 91, 93f D Roppy iris syndrome, 51 Danazol.56 5 Fluoroumcil. 124 Delayed hlpersensitivity reactions, 87 Foam medications, characteristics of, 85t Delirium, 27-28,2aL 41, 42 Folate associated disease/disorders, 18t Dental caries, 81 82,81f Folic acid supplementation, 59 Depression, 5, 47t,64 Fondaparinux,35 Dermatitis.86 87 Fracture risk in osteoporosis, Q55 Dermatitis herpetiformis, 103t Frailty, definition ol 41 Dermatofibromas, 120, 120f Frailty screening, Q21 Dermatologic disorders, 82 129, 83t, 85t Fungal infections, 65,67,83,101, 108, 108f, 116f, Q48 Dermatoph),tes, 106 108 Fusobocterium necrophorum, 80 Dermatoses, 102, 126 Dermographism, 90 91, 91f G Diabetes mellitus, 5, 39, Q47, Q109 Gallstones, 47t Dicloxacillin. 106 Garlic,20t Diet, modificationin. 43 44 Gastric banding,4S Dietary fiber, associated disease/disorders, 18t Gastric outlet syndrome, 47t Dietary supplements, 18-19 Gastric ulceration, 47t Dihydroxltestosterone, 52 Gastroesophageal refl ux, 47t Diphtheria toxoid, 12-13, Q40, Q63 Gastrointestinal agents, perioperative medication management, 3Ot Direct oral anticoagulants (DOACS), 35, 37 Gel medications, characteristics of, 85t 238

lndex Genitopelvic pain/penetration disorder, 64 Interprofessional communication, 25 Genitourinary syndrome, Ql lntertrigo, 89, 89f Geriatric Depression Scale, 5 I-PASS.26t Geriatric patients Iron. associated disease/disorders. l8t cervical cancer screening in, Q38 Itraconazole, 116 frailty, assessment of, 41, Q21 perioperative management, 41-42 J preoperative laboratory testing, Q30 Jock itch (tinea cruris), 106 Ginger,20t Gingival tissue, 82f x Cingivitis,81 82 Kava, 20t Ginko bilobo.20t Keratitis,6S 69,7Of Glaucoma, 7 2-73, 72f, 73f, Q37 Keratoacanthomas, 722-123, 123f, Q19 Glucocorticoids, 85, 851, 86t, Q4 Keratoconjunctivitis sicca, 71-72 Goblet cells,71-72 Kerion,107f Gonorrhea screening, 6, 7 t Kidney disease, perioperative management ol 40 Green nail syndrome, U6t Kidney stones,47t, 53t Guillain Barrd syndrome, 12 Koilonychia (spoon nails), 1161 Gupta Perioperative Risk for Myocardial Infarction or Cardiac Arrest (MICA) Calculator, 32 t Laboratory testing, preoperative, 28-29,29t, Q30, Q86 H Lean model. 22-23 Haemophilus inJlue nzoe |t'pe B, 15 Lemierre syndrome, 80 Halo nevi,120,l27f Length-time bias, screening and, 3 Hands, dermatitis, 88, 88f Lentigo maligna, 124, l25f Health care workers, screening for infectious diseases, 7t, Q63 Levothyroxine, 39 Health information technolory (HlT), 24 Libido, decreased, 48-49 Heaith literacy, 24-25 Lice (head, body, pubic),111, 1111 111t Health Literacy Tool Shed, 24 Lichen planopilaris, 1131, 115f Healthy People 2020, 16 Lichen planus, 117 , llgf,126-127 ,726f,127f, Q44 Hearing loss, 75 77,76t,77t, Q35 Lichenilication, characteristics ol 83t Heart failure, risk management, 33 Lifestyle, healthy behaviors, 16 18, 43, Q15, Q105 Hemodialysis patients, screening for infectious diseases, 7t Lindsay nails, 1161 Hemoglobin Ar. screening, 5 Linear IgA bullous dermatosis, 1031 Hemoglobin, preoperative testing, 29t Liraglutide,45t Hepatitis A virus immunization, 14 Liver chemistry preoperative, 29t Hepatitis B virus, 7t, 14 15, 15t Liver disease, 40 41, Q74 Hepatitis C virus screening, 6, 7t, Q43 Lotion medications, 85t Herbal supplements, 18-19, 20t-21t Louse-borne relapsing fever. lll Hernias,54 55 Lower urinary tract symptoms (LUTS), 51 52, 511, Q8 Herpes simplex virus, 110, U0t Low-molecular-weight heparin, 35 Herpes zoster, 13, 109-110, 109t Q6, Q36 Ludwig angina, 81 Hidradenitis suppurativa, 99-100, 1001 Q2 Lung cancer screening, 11-12, Q28 High risk populations, screening for infectious diseases, 7t Lungs, 34-35, 341, Q111. See olso Chronic obstructive pulmonary High value care, characteristics of, Q84 disease (COPD); Pulmonary assessments High Value Care Initiative,23 24 HIV screening, 6 7, 7t M Hives, characteristics of, 83t Ma huang/ephedra (ephedrine), 44 Hodgkin Iymphoma, itching in, 96 Macules, characteristics ol 83t Hormone therapy in menopause, Q101 Major adverse cardiac events (MACE), 31, 32t Human papillomavirus (HPV),14, 118, 119t, Q70 Malossezio furfur,loS Hydrocele,52 53,53f Male sexual dysfunction, 46 49, Q27 Hydrocortisone, IV 39-40 Malnutrition, 17, 4l- 42 Hyperkeratoic nodules, 122f Mammography, S Hypemensitivity vasculitis. 93 Marginal ulceration, 47t Hypertension, 5-6, 30t, 34, 491, 59, Q7. See clso Mastalgia,56 Pulmonary hypertension Measles, immunization, 14, Q82 Hyphema, traumatic, 68f Medical history physical examination,1-2, 2t Hypoactive sexual desire disorder, 48 49 Medicare, annual wellness visit, 1 Hypoglycemia, post bariatric surgery 47t Medication adherence, 21 22, Q78 Hypoparathyroidism, secondary 46 Medication errors, 19 21, 22t Hypopigmentation, 83 Medication management, 29, 30t Hypopyon,69 7o,7lf Medications Hypotension, post-bariatric surgery 47t perioperative, Q104 Hypothalamic pituitary adrenal axis (HPAA) side effects of,43t 45t. 48t, 591, Q13 suppression, 39-40 Melanocltic nevi, 72O 121, 1201, 1211 Hypothyroidism, 6 Melanoma, 124 126, 124( Q5, Q39 Melanonychia, 116t, 118, l181 125f I Melasma, 101 102, 1011 Q69 tgA pemphigus, characteristics of, 103t Melatonin, 19 Ileus, postoperative, 29 30, Q92 Meningococcal disease, 14, 15t Imiquimod, 124 Menopause, 61 63, 621, Q1, Q68, Q101 lmmunization, 12 16,59, Q4o, Q63, Q82. See olso specific vaccines Menstrual disorders. 60 61 Immunocompromise, influenza prevention in, Q59 Metabolic equivalents (METs), 32 Immunomodulators, topical, 86, Q115 Metformin. 19 Impetigo, 105 106, Q58 Microsporum spp., 106 lnfections. See specific infections Migraine with aura, contraceptive care in, Q14 lnfectious disease screening, 6-7 Milk thistle. 2ot lnflammatory dermatoses, 126 Minoxidil. 114 Influenza, 12, Q59 MMR (measles, mumps, rubella) vaccine, Q82 Inguinal hernias, 54-55 Model for End stage Liver Disease (MELD) score, 40 41 Injury prevention, l6 Model fbr Improvement, 22

Genitopelvic pain/penetration disorder, 64 Interprofessional communication, 25 Genitourinary syndrome, Ql lntertrigo, 89, 89f Geriatric Depression Scale, 5 I-PASS.26t Geriatric patients Iron. associated disease/disorders. l8t cervical cancer screening in, Q38 Itraconazole, 116 frailty, assessment of, 41, Q21 perioperative management, 41-42 J preoperative laboratory testing, Q30 Jock itch (tinea cruris), 106 Ginger,20t Gingival tissue, 82f x Cingivitis,81 82 Kava, 20t Ginko bilobo.20t Keratitis,6S 69,7Of Glaucoma, 7 2-73, 72f, 73f, Q37 Keratoacanthomas, 722-123, 123f, Q19 Glucocorticoids, 85, 851, 86t, Q4 Keratoconjunctivitis sicca, 71-72 Goblet cells,71-72 Kerion,107f Gonorrhea screening, 6, 7 t Kidney disease, perioperative management ol 40 Green nail syndrome, U6t Kidney stones,47t, 53t Guillain Barrd syndrome, 12 Koilonychia (spoon nails), 1161 Gupta Perioperative Risk for Myocardial Infarction or Cardiac Arrest (MICA) Calculator, 32 t Laboratory testing, preoperative, 28-29,29t, Q30, Q86 H Lean model. 22-23 Haemophilus inJlue nzoe |t'pe B, 15 Lemierre syndrome, 80 Halo nevi,120,l27f Length-time bias, screening and, 3 Hands, dermatitis, 88, 88f Lentigo maligna, 124, l25f Health care workers, screening for infectious diseases, 7t, Q63 Levothyroxine, 39 Health information technolory (HlT), 24 Libido, decreased, 48-49 Heaith literacy, 24-25 Lice (head, body, pubic),111, 1111 111t Health Literacy Tool Shed, 24 Lichen planopilaris, 1131, 115f Healthy People 2020, 16 Lichen planus, 117 , llgf,126-127 ,726f,127f, Q44 Hearing loss, 75 77,76t,77t, Q35 Lichenilication, characteristics ol 83t Heart failure, risk management, 33 Lifestyle, healthy behaviors, 16 18, 43, Q15, Q105 Hemodialysis patients, screening for infectious diseases, 7t Lindsay nails, 1161 Hemoglobin Ar. screening, 5 Linear IgA bullous dermatosis, 1031 Hemoglobin, preoperative testing, 29t Liraglutide,45t Hepatitis A virus immunization, 14 Liver chemistry preoperative, 29t Hepatitis B virus, 7t, 14 15, 15t Liver disease, 40 41, Q74 Hepatitis C virus screening, 6, 7t, Q43 Lotion medications, 85t Herbal supplements, 18-19, 20t-21t Louse-borne relapsing fever. lll Hernias,54 55 Lower urinary tract symptoms (LUTS), 51 52, 511, Q8 Herpes simplex virus, 110, U0t Low-molecular-weight heparin, 35 Herpes zoster, 13, 109-110, 109t Q6, Q36 Ludwig angina, 81 Hidradenitis suppurativa, 99-100, 1001 Q2 Lung cancer screening, 11-12, Q28 High risk populations, screening for infectious diseases, 7t Lungs, 34-35, 341, Q111. See olso Chronic obstructive pulmonary High value care, characteristics of, Q84 disease (COPD); Pulmonary assessments High Value Care Initiative,23 24 HIV screening, 6 7, 7t M Hives, characteristics of, 83t Ma huang/ephedra (ephedrine), 44 Hodgkin Iymphoma, itching in, 96 Macules, characteristics ol 83t Hormone therapy in menopause, Q101 Major adverse cardiac events (MACE), 31, 32t Human papillomavirus (HPV),14, 118, 119t, Q70 Malossezio furfur,loS Hydrocele,52 53,53f Male sexual dysfunction, 46 49, Q27 Hydrocortisone, IV 39-40 Malnutrition, 17, 4l- 42 Hyperkeratoic nodules, 122f Mammography, S Hypemensitivity vasculitis. 93 Marginal ulceration, 47t Hypertension, 5-6, 30t, 34, 491, 59, Q7. See clso Mastalgia,56 Pulmonary hypertension Measles, immunization, 14, Q82 Hyphema, traumatic, 68f Medical history physical examination,1-2, 2t Hypoactive sexual desire disorder, 48 49 Medicare, annual wellness visit, 1 Hypoglycemia, post bariatric surgery 47t Medication adherence, 21 22, Q78 Hypoparathyroidism, secondary 46 Medication errors, 19 21, 22t Hypopigmentation, 83 Medication management, 29, 30t Hypopyon,69 7o,7lf Medications Hypotension, post-bariatric surgery 47t perioperative, Q104 Hypothalamic pituitary adrenal axis (HPAA) side effects of,43t 45t. 48t, 591, Q13 suppression, 39-40 Melanocltic nevi, 72O 121, 1201, 1211 Hypothyroidism, 6 Melanoma, 124 126, 124( Q5, Q39 Melanonychia, 116t, 118, l181 125f I Melasma, 101 102, 1011 Q69 tgA pemphigus, characteristics of, 103t Melatonin, 19 Ileus, postoperative, 29 30, Q92 Meningococcal disease, 14, 15t Imiquimod, 124 Menopause, 61 63, 621, Q1, Q68, Q101 lmmunization, 12 16,59, Q4o, Q63, Q82. See olso specific vaccines Menstrual disorders. 60 61 Immunocompromise, influenza prevention in, Q59 Metabolic equivalents (METs), 32 Immunomodulators, topical, 86, Q115 Metformin. 19 Impetigo, 105 106, Q58 Microsporum spp., 106 lnfections. See specific infections Migraine with aura, contraceptive care in, Q14 lnfectious disease screening, 6-7 Milk thistle. 2ot lnflammatory dermatoses, 126 Minoxidil. 114 Influenza, 12, Q59 MMR (measles, mumps, rubella) vaccine, Q82 Inguinal hernias, 54-55 Model for End stage Liver Disease (MELD) score, 40 41 Injury prevention, l6 Model fbr Improvement, 22 239

Index Molluscum contagiosum, 109, 109f Periodontal disease- 81 Morbilliform drug eruptions, 9l, 931 Qlo Periodontitis. 81 Motivational interviewing, 171, Q15 Perioperative medications, Q11, Q104 Mumps immunization, 14, Q82 Perioperative medicine, 28-42 Periungual erlthema, 116t T Pertussis immunization, 12-13, Q63 Nail disorders, 115-119, ll6f, 1161, Q29 Pharyngitis,79, Q98 Nails, anatomy ol 115f Phentermine topiramate, 44, 45t Naltrexone-buproprion, 45t Photoallerry, 104-105, 1051 Nasal septum, vascular supply to,78f Photosensitivity disorders, I 04 National Patient Safety Coals, 24 Phototoxicity, l04 105,1051, Q95 National Surgical Quality Improvement Surgical Risk Calculator, 32 PHQ 2 depression screen, 5 Necrotizing ulcerative gingivitis, 81 82, 82f Physical activiry human health and, 18 Neisserio gonorrhoeoe, 52, 68 Physical examination, 1-2, Q87 Neomycin, allergenic properties, 87-88 Pigment disorders, 100-102 Nephrolithiasis, 53t Pimecrolimus. ST Neurologic disease, perioperative management of, 41 Pityriasis alba, 101 Nevi,120-121 Pityriasis rosea, 110, 110f Newest Vital Sign tool, 24 Pityriasisversicolor, 108 109 Nickel, allergenic properties, 87 Plan-Do-Study-Act (PDSA) cycle, 22 Nodular basal cell carcinoma, 123-124,123f Plaques, characteristics of, 83t Nodular melanoma, 125, 1251 Q39 Platelet counts, preoperative, 29t Nodules, characteristics ol 83t Pneumococcal disease immunization, 13t, Q20, Q121 Nonbullous impetigo, i06f Poison ivy, 88f Nummular dermatitis, 89, 89f Polycystic ovary syndrome, 5t, 61, 97, 113t Nutrition, 18, 18t Polyqthemia vera, itching in, 96 Polymorphous light eruptions, 104 105, 105f 0 Porphyria cutanea tarda, 102-104, 104f, Q120 Obesity. See olso Body mass index (BMl) Postanesthesia care unit, Ql24 classification of, 42t Postoperative care ,29-31, Q92 deflnition of.42-43 Postoperative ileus (POl), 29-30, Q92 epidemiolos/ of,42 43 Postpartum care, 59-60, 60t management ol 16,42-46, Q9, Q31, Q75 Postpartum depression, 64 screening for, 6 Potassium hydroxide (KOH), 65, 67, 83, 101, 108, 110, 116, Q48 Obstructive sleep apnea, 6, Q124 Powder medications, characteristics of, 85t Occipital adenopathy, 107 Preconception care, 58-59, 581, Q33 Ointments, charactedstics of, 85t Preeclampsia,58 OLDCARTS mnemonic, history taking, 1 Pregnancy Omega-3 fatty acids, 19 ectopic, 63 Onchomycosis, 116 117 gestational diabetes, Ql09 Onychogryphosis, 1161 immunizations during, Q40, Q82 Onycholysis, l17f perioperative management, 42 Onychomadesis, 1161 postpartum care, 59 60 Operational Excellence Model, 23 preconception care, 58-59, 58t Ophthalmologic evaluation, 67t preoperative testing, 29t Optic neuritis, T4 screening for infectious diseases, 7t Oral contraception, 56, 571, 98 Premature ejaculation, 48, Q27 Oral health.8l 82 Prevention, levels ofscreening for, 2 3 Orbital cellulitis. 68 Priapism,48 Orchitis, viral,53t Primary open-angle glaucoma (POAG), 72, 73t Orlistat,44,45t Probiotics. 19 Ospemifene,6S Progesterone-only contraception, 56, 57t Osteoporosis, 6. Q55 Propionibocte rium acne s, 97 Otitis externa, 77-78 Prostate cancer screening, 9-10, 9t, Q106 Otitis media, 77 -78, 77f Prostate-specific antigen (PSA), 9-11, 51 52 Overdiagnosis, screening principles, 3, Q93 Prostatitis, 53 54,54t, Q80, Q122 Overweight, classilication of; 42t Prosthetic heart valves, 37, 37t Oxybutynin, adverse effects ol 29 Proton pump inhibitors, 19 Pruritus, 68, 87, 88f, 91, 95 96, 951, 96f, 102, 108 P Psoriasis, 1171 118f, 126,126f. Q29 P2Y12 inhibitors, perioperative, 38 Psychiatric agents, perioperative, 30t Padua Prediction Score, 27t Psychogenic itch, 96 Palmar edema. 88f Pthirus pubis, U1t Pap test, 11 Pulmonary assessments, Q23 Papillary dermis, 82f Pulmonary function, 34-35, Qul Papule, characteristics ol 83t Pulmonary hypertension, 34, Q32 Paraneoplastic pemph igus. I 03t Pulpitis,81 Parkinson disease. 41 Pustules,83t,95f Paronychia, 117,117f Pyridoxine-associated disease/disorders, 18t Paroxetine,48 Patch medications, 85t o Patch testing,8Tf Quality improvement (QI), 19 25, Q84, Q119 Patches, characteristics of, 831, 107f Patient safety, 19,25, Q3 R Patient-centered medical home. 23 Rapid Estimate Adult Literacy in Medicine, 24 Pediculosis spp., 111, 1Ut Rashes, skin color and, 83 Pelvic examination, 61 Red blood cell transfusion. 38 39 Pelvic inllammatory disease (PID), 63 Red eye, 68 71, 69t Pelvic pain, 53 54, 63-64, Q57 Red lunulae, l16t Pemphigus foliaceus, 1031 Red yeast rice, 20t Pemphigus vulgaris, 102, 1021 1031, Q34 sd-Reductase inhibito6, 51 -52 Periodic health examination. I Referral bias, 3

Molluscum contagiosum, 109, 109f Periodontal disease- 81 Morbilliform drug eruptions, 9l, 931 Qlo Periodontitis. 81 Motivational interviewing, 171, Q15 Perioperative medications, Q11, Q104 Mumps immunization, 14, Q82 Perioperative medicine, 28-42 Periungual erlthema, 116t T Pertussis immunization, 12-13, Q63 Nail disorders, 115-119, ll6f, 1161, Q29 Pharyngitis,79, Q98 Nails, anatomy ol 115f Phentermine topiramate, 44, 45t Naltrexone-buproprion, 45t Photoallerry, 104-105, 1051 Nasal septum, vascular supply to,78f Photosensitivity disorders, I 04 National Patient Safety Coals, 24 Phototoxicity, l04 105,1051, Q95 National Surgical Quality Improvement Surgical Risk Calculator, 32 PHQ 2 depression screen, 5 Necrotizing ulcerative gingivitis, 81 82, 82f Physical activiry human health and, 18 Neisserio gonorrhoeoe, 52, 68 Physical examination, 1-2, Q87 Neomycin, allergenic properties, 87-88 Pigment disorders, 100-102 Nephrolithiasis, 53t Pimecrolimus. ST Neurologic disease, perioperative management of, 41 Pityriasis alba, 101 Nevi,120-121 Pityriasis rosea, 110, 110f Newest Vital Sign tool, 24 Pityriasisversicolor, 108 109 Nickel, allergenic properties, 87 Plan-Do-Study-Act (PDSA) cycle, 22 Nodular basal cell carcinoma, 123-124,123f Plaques, characteristics of, 83t Nodular melanoma, 125, 1251 Q39 Platelet counts, preoperative, 29t Nodules, characteristics ol 83t Pneumococcal disease immunization, 13t, Q20, Q121 Nonbullous impetigo, i06f Poison ivy, 88f Nummular dermatitis, 89, 89f Polycystic ovary syndrome, 5t, 61, 97, 113t Nutrition, 18, 18t Polyqthemia vera, itching in, 96 Polymorphous light eruptions, 104 105, 105f 0 Porphyria cutanea tarda, 102-104, 104f, Q120 Obesity. See olso Body mass index (BMl) Postanesthesia care unit, Ql24 classification of, 42t Postoperative care ,29-31, Q92 deflnition of.42-43 Postoperative ileus (POl), 29-30, Q92 epidemiolos/ of,42 43 Postpartum care, 59-60, 60t management ol 16,42-46, Q9, Q31, Q75 Postpartum depression, 64 screening for, 6 Potassium hydroxide (KOH), 65, 67, 83, 101, 108, 110, 116, Q48 Obstructive sleep apnea, 6, Q124 Powder medications, characteristics of, 85t Occipital adenopathy, 107 Preconception care, 58-59, 581, Q33 Ointments, charactedstics of, 85t Preeclampsia,58 OLDCARTS mnemonic, history taking, 1 Pregnancy Omega-3 fatty acids, 19 ectopic, 63 Onchomycosis, 116 117 gestational diabetes, Ql09 Onychogryphosis, 1161 immunizations during, Q40, Q82 Onycholysis, l17f perioperative management, 42 Onychomadesis, 1161 postpartum care, 59 60 Operational Excellence Model, 23 preconception care, 58-59, 58t Ophthalmologic evaluation, 67t preoperative testing, 29t Optic neuritis, T4 screening for infectious diseases, 7t Oral contraception, 56, 571, 98 Premature ejaculation, 48, Q27 Oral health.8l 82 Prevention, levels ofscreening for, 2 3 Orbital cellulitis. 68 Priapism,48 Orchitis, viral,53t Primary open-angle glaucoma (POAG), 72, 73t Orlistat,44,45t Probiotics. 19 Ospemifene,6S Progesterone-only contraception, 56, 57t Osteoporosis, 6. Q55 Propionibocte rium acne s, 97 Otitis externa, 77-78 Prostate cancer screening, 9-10, 9t, Q106 Otitis media, 77 -78, 77f Prostate-specific antigen (PSA), 9-11, 51 52 Overdiagnosis, screening principles, 3, Q93 Prostatitis, 53 54,54t, Q80, Q122 Overweight, classilication of; 42t Prosthetic heart valves, 37, 37t Oxybutynin, adverse effects ol 29 Proton pump inhibitors, 19 Pruritus, 68, 87, 88f, 91, 95 96, 951, 96f, 102, 108 P Psoriasis, 1171 118f, 126,126f. Q29 P2Y12 inhibitors, perioperative, 38 Psychiatric agents, perioperative, 30t Padua Prediction Score, 27t Psychogenic itch, 96 Palmar edema. 88f Pthirus pubis, U1t Pap test, 11 Pulmonary assessments, Q23 Papillary dermis, 82f Pulmonary function, 34-35, Qul Papule, characteristics ol 83t Pulmonary hypertension, 34, Q32 Paraneoplastic pemph igus. I 03t Pulpitis,81 Parkinson disease. 41 Pustules,83t,95f Paronychia, 117,117f Pyridoxine-associated disease/disorders, 18t Paroxetine,48 Patch medications, 85t o Patch testing,8Tf Quality improvement (QI), 19 25, Q84, Q119 Patches, characteristics of, 831, 107f Patient safety, 19,25, Q3 R Patient-centered medical home. 23 Rapid Estimate Adult Literacy in Medicine, 24 Pediculosis spp., 111, 1Ut Rashes, skin color and, 83 Pelvic examination, 61 Red blood cell transfusion. 38 39 Pelvic inllammatory disease (PID), 63 Red eye, 68 71, 69t Pelvic pain, 53 54, 63-64, Q57 Red lunulae, l16t Pemphigus foliaceus, 1031 Red yeast rice, 20t Pemphigus vulgaris, 102, 1021 1031, Q34 sd-Reductase inhibito6, 51 -52 Periodic health examination. I Referral bias, 3 240

lndex Reproductive health, 56-60 Supplements Respiratory distress, prevention of, 28 after bariatric surgery 46t Reticular dermis, 82f CVD prevention and, Q114 Retinal artery occlusion, 74 perioperative, 30t Retinal detachment, 74, Q53 safety ol Q60 Retinal vein occlusion, 74 weight loss,44 Retinoids, topical, 85t,86, 97 Suspensions, characteristics of, 85t Revised Cardiac Risk Index (RCRI), 31--32,32t Sweet slaldrome, 128 729, 729f , 729t Rheumatologic agents, perioperative, 301, Q11 Syphilis screening, 7t Rheumatologic disease, 41 SJ,Btem lupus erlthematosus, 102 Rhinitis. T9 Rhinophyma, 99, 99f T Rickettsia prouozekii, 711 Tacrolimus, ST Rinne test, 75, 77t Tadalafil,48 Rosacea, 98-99,98f, 991 991, Q107 Tamoxifen,56 Roux en Y gastric bypass,45 Tazarotene,9T Rubella immunization, 14, Q82 Team based care, 25 Team/family meetings, 26t s Telangiectasias, 831, 98-99 Salivary gland disorders, 80-81 Telogen effluvium, 1131, 114 Sorcoptes scobiei, 111 Teratogenic medications, 59t Saw palmetto, 201, 52 Terbinafine, u6 SBAR technique, 22, 26t Terry nails, 116t Scabies, 111, 1111 1111, Q73 Testicles, ultrasound of 53f Scales, characteristics of, 83t Testicular cance! 53t Scorcoptes scabiei mites, 112f Testicular pain, 52, 53t Scleritis, 69-7O,7Of Testicular torsion, 52, Q71 SCORTEN scale, 94, 95t Testosterone levels, 48 Screening, 4 12, 7Ot, 43, 7 6t, Q7, Q2l, Q28, Q38, Q43, Testosterone therap)l 65 Qs2, Q67, Qe7, Q1o6, Q1oe, Q117, Q123. Tetanus immunization, 12-13, 16, Q40, Q63 See olso specfic disorders Tetanus toxoid, reduced diphtheria toxoid, and acellular perhrssis bias,3 (Tdap) vaccine, 12 13,16, Q40 effect on survival after diagnosis, 3f Thiamine associated disease/disorders, 18t length time bias and, 3, 3f Thrombocytopenia, 38-39 overdiagnosis and, 3, Q93 Thyroid disease, 39, 96, Q54 principles of,2 3 Thyroid dysfunction, screening for, 6 recommendations, 3-4 Thyroid storm, 39 Scrotal pain, 52, 53t Thyroiditis, postpartum, 59 Seborrheic dermatitis, 88-89, 89f, Q12 Tinea,106 108 Seborrheic keratoses, 119, 119t Q81 capitis (scalp),106 Selective serotonin reuptake inhibitor (SSRI), 48 corporis,106, 107f Sex hormone binding globulin (SHBG), 50 cruris (jock itch) ,706,7o7f Sexual dysfunction faciei (face), 106 female,64 65 manuum (hand),106 male,46-49,Q27 pedis (athlete's foot), 106,108f, Q91 Short Assessment ofHealth Literacy, 24 versicolor, l09f Sialadinitis,8l Tinnitus, TT Sibutramine for obesity, 44 Tobacco cessation, 16 Sigmoidoscopy, 10t Toenails, 116-118, 118f Sildenafil,48 Tofacitinib,4l Sinusitis, 79, 79t, Q26 Tongue blade stroke induced dermographism, 91f Six Sigma,23 Topical medications, dermatologic disorders, 84 85. Skin See olso specific type biopsies, 84t effectiveness, 84-85 chemical reactions, 92t frequently used, 85t drug reactions, 92t vehicles for, 85t infections, 105-u1 Toxic epidermal necrolysis (TEN), 93-95, I 4f , 9 4t, Q76, Q99 infl ammatory disorders, QUs Trachyonychia, 1161 lesion morpholory, 82 Traction alopecia, 114f lesions, 83t Transfusions, red cells, 38-39 structure of. 82f Transgender patients, Q18 Skin tags, 120 Transient ischemic attack (TIA), perioperative, 41 Sleep apnea, 35t Transitions of care , 22 , Q119 Sleep patterns, lT Traumatic alopecia, 113, 1131 Sleeve gastrectomy, 45, Q31 Trench fever, 111 Smoking, T3-74, 126 Tretinoin,9T Social isolation, screening for, Q52 Trichomoniasis, 661, 67, Q85 Solution medications, 85t TnchophAton rubrum,l06 Soy,20t Trichophuton spp., 106 Sports, physical examinations, Q87 Trimethoprim-polymyxin B, 68, Q17 Squamous cell carcinoma (SCC), 118, 122-123, 122f, 123f, Q88 Trimethoprim-sulfamethoxazole, Q122 st. John's wort. 21t Tuberculosis screening, 7t Staphylococcal scalded skin syndrome, 106 T),rnpanic membrane retraction, 75f Stensen duct. 81 Tlphus, i11 Sterilization, male, 49-50 Stevens-Johnson s),ndrome (SJS), 93-95, 94f,94t, Ql6, Q99 U STOP BANG tool,35, 35t Ulcers, characteristics of, 83t Stratum corneum, 82f Upper respiratory tlact infection, 79-80 Stress reduction, 17 Urinalysis, preoperative, 29t Stroke,41, Q72 Urinary retention, po$operative. 29 Subconjunctival hemorrhage, 70, 71f Urinary tmct, lower, 51t Substance use disorder screening, 7-8 Urticaria, 90-91, 90f

Reproductive health, 56-60 Supplements Respiratory distress, prevention of, 28 after bariatric surgery 46t Reticular dermis, 82f CVD prevention and, Q114 Retinal artery occlusion, 74 perioperative, 30t Retinal detachment, 74, Q53 safety ol Q60 Retinal vein occlusion, 74 weight loss,44 Retinoids, topical, 85t,86, 97 Suspensions, characteristics of, 85t Revised Cardiac Risk Index (RCRI), 31--32,32t Sweet slaldrome, 128 729, 729f , 729t Rheumatologic agents, perioperative, 301, Q11 Syphilis screening, 7t Rheumatologic disease, 41 SJ,Btem lupus erlthematosus, 102 Rhinitis. T9 Rhinophyma, 99, 99f T Rickettsia prouozekii, 711 Tacrolimus, ST Rinne test, 75, 77t Tadalafil,48 Rosacea, 98-99,98f, 991 991, Q107 Tamoxifen,56 Roux en Y gastric bypass,45 Tazarotene,9T Rubella immunization, 14, Q82 Team based care, 25 Team/family meetings, 26t s Telangiectasias, 831, 98-99 Salivary gland disorders, 80-81 Telogen effluvium, 1131, 114 Sorcoptes scobiei, 111 Teratogenic medications, 59t Saw palmetto, 201, 52 Terbinafine, u6 SBAR technique, 22, 26t Terry nails, 116t Scabies, 111, 1111 1111, Q73 Testicles, ultrasound of 53f Scales, characteristics of, 83t Testicular cance! 53t Scorcoptes scabiei mites, 112f Testicular pain, 52, 53t Scleritis, 69-7O,7Of Testicular torsion, 52, Q71 SCORTEN scale, 94, 95t Testosterone levels, 48 Screening, 4 12, 7Ot, 43, 7 6t, Q7, Q2l, Q28, Q38, Q43, Testosterone therap)l 65 Qs2, Q67, Qe7, Q1o6, Q1oe, Q117, Q123. Tetanus immunization, 12-13, 16, Q40, Q63 See olso specfic disorders Tetanus toxoid, reduced diphtheria toxoid, and acellular perhrssis bias,3 (Tdap) vaccine, 12 13,16, Q40 effect on survival after diagnosis, 3f Thiamine associated disease/disorders, 18t length time bias and, 3, 3f Thrombocytopenia, 38-39 overdiagnosis and, 3, Q93 Thyroid disease, 39, 96, Q54 principles of,2 3 Thyroid dysfunction, screening for, 6 recommendations, 3-4 Thyroid storm, 39 Scrotal pain, 52, 53t Thyroiditis, postpartum, 59 Seborrheic dermatitis, 88-89, 89f, Q12 Tinea,106 108 Seborrheic keratoses, 119, 119t Q81 capitis (scalp),106 Selective serotonin reuptake inhibitor (SSRI), 48 corporis,106, 107f Sex hormone binding globulin (SHBG), 50 cruris (jock itch) ,706,7o7f Sexual dysfunction faciei (face), 106 female,64 65 manuum (hand),106 male,46-49,Q27 pedis (athlete's foot), 106,108f, Q91 Short Assessment ofHealth Literacy, 24 versicolor, l09f Sialadinitis,8l Tinnitus, TT Sibutramine for obesity, 44 Tobacco cessation, 16 Sigmoidoscopy, 10t Toenails, 116-118, 118f Sildenafil,48 Tofacitinib,4l Sinusitis, 79, 79t, Q26 Tongue blade stroke induced dermographism, 91f Six Sigma,23 Topical medications, dermatologic disorders, 84 85. Skin See olso specific type biopsies, 84t effectiveness, 84-85 chemical reactions, 92t frequently used, 85t drug reactions, 92t vehicles for, 85t infections, 105-u1 Toxic epidermal necrolysis (TEN), 93-95, I 4f , 9 4t, Q76, Q99 infl ammatory disorders, QUs Trachyonychia, 1161 lesion morpholory, 82 Traction alopecia, 114f lesions, 83t Transfusions, red cells, 38-39 structure of. 82f Transgender patients, Q18 Skin tags, 120 Transient ischemic attack (TIA), perioperative, 41 Sleep apnea, 35t Transitions of care , 22 , Q119 Sleep patterns, lT Traumatic alopecia, 113, 1131 Sleeve gastrectomy, 45, Q31 Trench fever, 111 Smoking, T3-74, 126 Tretinoin,9T Social isolation, screening for, Q52 Trichomoniasis, 661, 67, Q85 Solution medications, 85t TnchophAton rubrum,l06 Soy,20t Trichophuton spp., 106 Sports, physical examinations, Q87 Trimethoprim-polymyxin B, 68, Q17 Squamous cell carcinoma (SCC), 118, 122-123, 122f, 123f, Q88 Trimethoprim-sulfamethoxazole, Q122 st. John's wort. 21t Tuberculosis screening, 7t Staphylococcal scalded skin syndrome, 106 T),rnpanic membrane retraction, 75f Stensen duct. 81 Tlphus, i11 Sterilization, male, 49-50 Stevens-Johnson s),ndrome (SJS), 93-95, 94f,94t, Ql6, Q99 U STOP BANG tool,35, 35t Ulcers, characteristics of, 83t Stratum corneum, 82f Upper respiratory tlact infection, 79-80 Stress reduction, 17 Urinalysis, preoperative, 29t Stroke,41, Q72 Urinary retention, po$operative. 29 Subconjunctival hemorrhage, 70, 71f Urinary tmct, lower, 51t Substance use disorder screening, 7-8 Urticaria, 90-91, 90f 241

lndex Urticarial vasculitis, Q50 Verruca plaque, u9f Urushiol,87 Verruca vulgaris, u9-u0 Users ofinjection drugs, infectious disease screening in,7t Vesicles, characteristics of, 83t Uterine bleeding, abnormal, 60-61, 60t Vitamin D analogues, 851,126 Uveitis,70,71f Vitamin D deficiency,46, 46t Vitamin K antagonist therapy, 38t v Vitamins, r8, 18t, 19, QU4 Vacuum erection device, 48 Vitiligo, 83, 100-101, rori Qs4 Vaginal atrophy, 62f Volunteer bias, 3 Vaginal discharge, Qx8 veginitis, 65-67 , 66t,67f, Q118 w Veginosis, bacterial, 65, 66t, Q25 Warfarin, perioperative, Q56 Valacyclovir, uo warts, 119-120,119f Velerian,2lt Weber test, 75, zt Valve replacement, Q41 Weight gatut medications and, Q108 Vardenafil,4S Weight loss, 45t, 47t, Qlo8 Varicella, 109-110, Uot Wellness counseling, 17 immunization, 13 Wharto duct,81 Varicocele, 52-53 Wheals, characteristics of, 83t Vascular heart disease, risk management, 33-34 Wood lamps,83, l0l, 106 Vasculitis, urticarial, Q50 Vasectomy,49-50, 50t Y Venous stasis dermatitis, 90,90f Yellow nails, u6t, 1uf Venous thromboembolic disease, 38, Q79, Q116 Venous thromboembolism (VTE) , 27 -28 , 27t, 35-37 , 36t 2 Verruca plana, U9-120 Zike virus, 59 Verruca plantaris, 119-120 Znc supplements, 19 I i l

Urticarial vasculitis, Q50 Verruca plaque, u9f Urushiol,87 Verruca vulgaris, u9-u0 Users ofinjection drugs, infectious disease screening in,7t Vesicles, characteristics of, 83t Uterine bleeding, abnormal, 60-61, 60t Vitamin D analogues, 851,126 Uveitis,70,71f Vitamin D deficiency,46, 46t Vitamin K antagonist therapy, 38t v Vitamins, r8, 18t, 19, QU4 Vacuum erection device, 48 Vitiligo, 83, 100-101, rori Qs4 Vaginal atrophy, 62f Volunteer bias, 3 Vaginal discharge, Qx8 veginitis, 65-67 , 66t,67f, Q118 w Veginosis, bacterial, 65, 66t, Q25 Warfarin, perioperative, Q56 Valacyclovir, uo warts, 119-120,119f Velerian,2lt Weber test, 75, zt Valve replacement, Q41 Weight gatut medications and, Q108 Vardenafil,4S Weight loss, 45t, 47t, Qlo8 Varicella, 109-110, Uot Wellness counseling, 17 immunization, 13 Wharto duct,81 Varicocele, 52-53 Wheals, characteristics of, 83t Vascular heart disease, risk management, 33-34 Wood lamps,83, l0l, 106 Vasculitis, urticarial, Q50 Vasectomy,49-50, 50t Y Venous stasis dermatitis, 90,90f Yellow nails, u6t, 1uf Venous thromboembolic disease, 38, Q79, Q116 Venous thromboembolism (VTE) , 27 -28 , 27t, 35-37 , 36t 2 Verruca plana, U9-120 Zike virus, 59 Verruca plantaris, 119-120 Znc supplements, 19 I i l l I l

Urticarial vasculitis, Q50 Verruca plaque, u9f Urushiol,87 Verruca vulgaris, u9-u0 Users ofinjection drugs, infectious disease screening in,7t Vesicles, characteristics of, 83t Uterine bleeding, abnormal, 60-61, 60t Vitamin D analogues, 851,126 Uveitis,70,71f Vitamin D deficiency,46, 46t Vitamin K antagonist therapy, 38t v Vitamins, r8, 18t, 19, QU4 Vacuum erection device, 48 Vitiligo, 83, 100-101, rori Qs4 Vaginal atrophy, 62f Volunteer bias, 3 Vaginal discharge, Qx8 veginitis, 65-67 , 66t,67f, Q118 w Veginosis, bacterial, 65, 66t, Q25 Warfarin, perioperative, Q56 Valacyclovir, uo warts, 119-120,119f Velerian,2lt Weber test, 75, zt Valve replacement, Q41 Weight gatut medications and, Q108 Vardenafil,4S Weight loss, 45t, 47t, Qlo8 Varicella, 109-110, Uot Wellness counseling, 17 immunization, 13 Wharto duct,81 Varicocele, 52-53 Wheals, characteristics of, 83t Vascular heart disease, risk management, 33-34 Wood lamps,83, l0l, 106 Vasculitis, urticarial, Q50 Vasectomy,49-50, 50t Y Venous stasis dermatitis, 90,90f Yellow nails, u6t, 1uf Venous thromboembolic disease, 38, Q79, Q116 Venous thromboembolism (VTE) , 27 -28 , 27t, 35-37 , 36t 2 Verruca plana, U9-120 Zike virus, 59 Verruca plantaris, 119-120 Znc supplements, 19 I i l l I l \ 242 i i

l I l \ 242 i i i